Compare Lockheed Martin Corporation (LMT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Neurocrine Biosciences Inc — how do they compare? Lockheed Martin Corporation trades at $508.08 (market cap $117.22B), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: Lockheed Martin Corporation is far larger — about 8.2× Neurocrine Biosciences Inc's market cap, and Lockheed Martin Corporation pays a 2.72% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and Neurocrine Biosciences Inc for 23 Days on average.
| LMT | NBIX | |
|---|---|---|
Market Cap | $117.22B | $14.36B |
Volume | 1,101,121 | 1,237,180 |
Sector | Industrials | Health |
52-Week High | $676.70 | $185.50 |
52-Week Low | $439.19 | $123.10 |
Typical Hold Time | 86 Days | 23 Days |
Enterprise Value | $133.96B | $14.37B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $509.59, up 2.08% over the past day, with a bearish technical signal but strong analyst consensus. The company reported mixed quarterly earnings, missing in Q4 2025 and Q1 2026 but beating in Q2 2026, while revenue and cash flow trends show growth. Recent news highlights innovation in AI and autonomous systems, dividend increases, and ongoing defense contracts, supporting a positive long-term outlook despite near-term volatility.
LMT presents a compelling investment case with a consensus price target of $635.33, implying significant upside, backed by robust cash flows and a dominant defense market position. Risks include reliance on government spending, fixed-price contract volatility, and rising debt levels, but the stock's current valuation and dividend track record offer a margin of safety for patient investors.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
